Section 1 provides that health plans that have a multi-tier benefit structure for prescription drugs are in compliance with this section regulating cancer chemotherapy treatment if the plan does not include orally administered anticancer medication in the coverage tier with the highest cost-sharing.

Sections 2 and 4 restore specified rating requirements for grandfathered plans that were deleted in legislation two years ago.

Sections 3 and 5 are technical correction changes related to dependent children and portability of coverage, respectively.

Section 6 extends the amount of time a consumer has to request external review of adverse determination by an insurer from 6 to 9 months.

CBS/tg